Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
20 studies found for:    teriflunomide
Show Display Options
Rank Status Study
1 Not yet recruiting Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
Conditions: Teriflunomide Elimination;   Healthy Volunteers
Interventions: Drug: teriflunomide;   Drug: Colestipol
2 Completed
Has Results
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide;   Drug: Placebo (for teriflunomide);   Drug: Glatiramer Acetate (GA)
3 Completed
Has Results
Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide;   Drug: Placebo (for Teriflunomide);   Drug: Interferon-β
4 Recruiting Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
Condition: Multiple Sclerosis
Intervention: Drug: TERIFLUNOMIDE HMR1726
5 Recruiting Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide
Condition: Multiple Sclerosis
Intervention: Drug: teriflunomide
6 Completed
Has Results
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide;   Drug: Placebo (for teriflunomide)
7 Completed Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide;   Drug: Placebo (placebo for teriflunomide)
8 Completed
Has Results
Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide;   Drug: Placebo (for teriflunomide);   Drug: Interferon-β [IFN-β];   Drug: Glatiramer Acetate [GA]
9 Active, not recruiting
Has Results
An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Placebo (for teriflunomide);   Drug: Teriflunomide
10 Active, not recruiting Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide;   Drug: Placebo (for teriflunomide)
11 Terminated
Has Results
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide;   Drug: Placebo (for teriflunomide);   Drug: Interferon-beta (IFN-beta)
12 Active, not recruiting
Has Results
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: interferon β-1a;   Drug: teriflunomide
13 Completed
Has Results
Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
Condition: Multiple Sclerosis
Interventions: Drug: teriflunomide;   Drug: Interferon-β-1;   Biological: Influenza vaccine
14 Completed A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide HMR1726;   Drug: cholestyramine
15 Recruiting Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
Condition: Multiple Sclerosis
Intervention: Other: MRI
16 Active, not recruiting Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: teriflunomide HMR1726;   Drug: cholestyramine;   Drug: charcoal
17 Active, not recruiting Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Condition: Multiple Sclerosis
Intervention: Drug: teriflunomide (HMR1726)
18 Recruiting Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide HMR1726;   Drug: Placebo
19 Completed Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment
Condition: Renal Impairment
Interventions: Drug: Teriflunomide HMR1726;   Drug: Cholestyramine
20 Active, not recruiting Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: teriflunomide (HMR1726)

Indicates status has not been verified in more than two years